Dividend momentum STERIS demonstrates strong and growing cash returns with a raised quarterly dividend and 21st consecutive year of dividend growth, signaling robust free cash flow and financial stability that can support expansion projects, maintenance contracts, and capital expenditure programs in healthcare facilities.

Healthcare leadership As a leading infection prevention and sterilization provider serving healthcare, pharmaceutical, and medical device customers, STERIS offers recurring opportunities for facility sterilization services, infection control products, and value-based service contracts across hospitals, clinics, and research sites.

Global scale With over 18,000 associates and 10,001+ employees worldwide, plus a sizable customer-facing team, there are cross-border rollout opportunities for new products, extended service offerings, and regional compliance solutions in diverse markets.

Growth drivers Stock-market activity and analyst coverage indicate expectations of steady revenue growth across Healthcare, AST, and Life Sciences segments, suggesting demand for upgrades, new sterilization technologies, and consumables tied to expanding healthcare and pharma operations.

Strategic investments Active institutional interest from funds like Arrowstreet and other investors signals favorable capital markets support for strategic initiatives; this could align with sales opportunities around capital equipment modernization, service packages, and long-term maintenance agreements.